Favorable Media Coverage Somewhat Unlikely to Affect iShares Nasdaq Biotechnology Index Fund (IBB) Stock Price
News coverage about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has been trending positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. iShares Nasdaq Biotechnology Index Fund earned a media sentiment score of 0.36 on Accern’s scale. Accern also assigned news headlines about the financial services provider an impact score of 46.7183202514193 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Daniel Devine & Co Buys Costco Wholesale Corp, Starbucks Corp, iShares MSCI EAFE, Sells Procter & Gamble Co … – GuruFocus.com (gurufocus.com)
- Did iShares Trust – iShares Nasdaq Biotechnology ETF (IBB) Create Value For Investors Over The Past Year? (finance.yahoo.com)
- Biotech Funds Flashing Sell Signals (finance.yahoo.com)
- Can Biotech ETFs Continue Their Impressive Run In 2018? (IBB) (etfdailynews.com)
iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) traded down $2.88 on Tuesday, hitting $308.33. The stock had a trading volume of 881,900 shares, compared to its average volume of 1,110,708. iShares Nasdaq Biotechnology Index Fund has a 1-year low of $261.65 and a 1-year high of $342.50.
ILLEGAL ACTIVITY NOTICE: “Favorable Media Coverage Somewhat Unlikely to Affect iShares Nasdaq Biotechnology Index Fund (IBB) Stock Price” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/favorable-media-coverage-somewhat-unlikely-to-affect-ishares-nasdaq-biotechnology-index-fund-ibb-stock-price/1718289.html.
iShares Nasdaq Biotechnology Index Fund Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with Analyst Ratings Network's FREE daily email newsletter.